Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.79 |
| ▸ | NPC1 | O15118 | 3/20 | 0.79 |
| ▸ | RAB9A | P51151 | 3/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455830 | 1.00 | FLT3 (1.00) | FLT3MAPTNPC1RAB9ANPSR1 | |
| SCHEMBL5453252 | 0.84 | FLT3 (0.73) | FLT3MAPTNPC1RAB9ANPSR1 | |
| SCHEMBL5453258 | 0.84 | FLT3 (0.73) | FLT3MAPTNPC1RAB9ANPSR1 | |
| SCHEMBL5457914 | 0.83 | FLT3 (0.70) | FLT3MAPTNPC1RAB9ALMNA | |
| SCHEMBL5457913 | 0.83 | FLT3 (0.70) | FLT3MAPTNPC1RAB9ALMNA | |
| SCHEMBL3923490 | 0.82 | FLT3 (1.00) | FLT3MAPTNPC1RAB9ANPSR1 | |
| SCHEMBL3923491 | 0.82 | FLT3 (1.00) | FLT3MAPTNPC1RAB9ANPSR1 | |
| SCHEMBL8289714 | 0.82 | FLT3 (0.69) | FLT3MAPTNPC1RAB9ALMNA | |
| SCHEMBL3128198 | 0.79 | FLT3 (1.00) | FLT3MAPTNPC1RAB9ALMNA | |
| SCHEMBL5450860 | 0.78 | MEN1 (0.78) | FLT3MAPTNPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FLT3 3509/4885MAPT 21/4885NPC1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.